Shandong Sito Bio-technology Co., Ltd. (SHE:300583)
China · Delayed Price · Currency is CNY 13.27
-0.26 (-1.92%)
Oct 14, 2026, 11:59 AM CST
SHE:300583 Revenue
Shandong Sito Bio-technology had revenue of 284.69M CNY in the quarter ending June 30, 2026, with 14.83% growth. This brings the company's revenue in the last twelve months to 1.12B, up 23.05% year-over-year. In the year 2025, Shandong Sito Bio-technology had annual revenue of 1.02B with 4.77% growth. That makes Shandong Sito Bio-technology the 18,740th largest company in the world by revenue and 3,417th in China.
Revenue (ttm)
1.12B
Revenue Growth
+23.05%
P/S Ratio
2.29
Revenue / Employee
1.13M
Employees
990
Market Cap
2.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.02B | 46.27M | 4.77% |
| Dec 31, 2024 | 970.60M | -309.18M | -24.16% |
| Dec 31, 2023 | 1.28B | -32.33M | -2.46% |
| Jan 1, 2023 | 1.31B | 109.49M | 9.10% |
| Jan 1, 2022 | 1.20B | 289.44M | 31.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beijing Kawin Technology Share-Holding | 1.23B |
| Shanghai Universal Biotech | 1.15B |
| Guangdong VTR Bio-Tech | 814.07M |
| Jilin Jian Yisheng Pharmaceutical | 650.83M |
| Hubei Goto Biopharm Group | 650.05M |
| Zhejiang Shouxiangu Pharmaceutical | 616.54M |
| Suzhou Fushilai Pharmaceutical | 394.29M |
| Yantai Zhenghai Biotechnology | 336.07M |